In yesterday’s Wall Street session, ImmunityBio Inc. (NASDAQ:IBRX) shares traded at $2.65, down -5.69% from the previous session.
IBRX stock price is now -7.69% away from the 50-day moving average and -29.12% away from the 200-day moving average. The market capitalization of the company currently stands at $1.19B.
With the price target reduced from $10 to $4, Piper Sandler Downgraded its rating from Overweight to Neutral for ImmunityBio Inc. (NASDAQ: IBRX).
In other news, BLASZYK MICHAEL D, Director bought 71,915 shares of the company’s stock on Jun 05. The stock was bought for $198,023 at an average price of $2.75. Upon completion of the transaction, the Director now directly owns 71,915 shares in the company, valued at $0.19 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 02, Director Brennan John Owen bought 25,000 shares of the business’s stock. A total of $70,700 was incurred on buying the stock at an average price of $2.83. This leaves the insider owning 25,000 shares of the company worth $66250.0. Insiders disposed of 46,465 shares of company stock worth roughly $0.12 million over the past 1 year. A total of 72.71% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IBRX stock. A new stake in ImmunityBio Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $15,359,000. TANG CAPITAL MANAGEMENT LLC invested $2,904,000 in shares of IBRX during the first quarter. In the first quarter, MILLENNIUM MANAGEMENT LLC acquired a new stake in ImmunityBio Inc. valued at approximately $1,380,000. SQUAREPOINT OPS LLC acquired a new stake in IBRX for approximately $1,277,000. OCCUDO QUANTITATIVE STRATEGIES LP purchased a new stake in IBRX valued at around $1,057,000 in the second quarter. In total, there are 211 active investors with 10.30% ownership of the company’s stock.
Monday morning saw ImmunityBio Inc. (NASDAQ: IBRX) opened at $2.7500. During the past 12 months, ImmunityBio Inc. has had a low of $1.21 and a high of $7.80. The fifty day moving average price for IBRX is $2.7994 and a two-hundred day moving average price translates $3.7243 for the stock.
The latest earnings results from ImmunityBio Inc. (NASDAQ: IBRX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.27, missing analysts’ expectations of -$0.22 by -0.05. This compares to -$0.26 EPS in the same period last year. The company reported revenue of $0.36 million for the quarter, compared to $14000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2471.43 percent. For the current quarter, analysts expect IBRX to generate $360k in revenue.
ImmunityBio Inc.(IBRX) Company Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
